Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0C7JH
|
||||
Former ID |
DIB015122
|
||||
Drug Name |
TP-9201
|
||||
Synonyms |
Acetyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-arginyl-glycyl-L-aspartyl-L-(4-O-methyl)-tyrosyl-L-arginyl-L-cysteinamide cyclic 1-9-disulfide
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Thrombosis [ICD9: 437.6, 453, 671.5, 671.9; ICD10:I80-I82] | Discontinued in Phase 1 | [545013] | ||
Structure |
Download2D MOL |
||||
Formula |
C45H69N17O14S2
|
||||
Canonical SMILES |
CC(=O)NC1CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(N<br />C(=O)C2CCCN2C(=O)C(NC1=O)CC(=O)N)CCCN=C(N)N)CC(=O)O)CC3<br />=CC=C(C=C3)OC)CCCN=C(N)N)C(=O)N
|
||||
InChI |
1S/C45H69N17O14S2/c1-22(63)55-31-21-78-77-20-30(36(47)68)61-38(70)26(7-4-14-53-45(50)51)57-39(71)27(16-23-9-11-24(76-2)12-10-23)59-40(72)28(18-35(66)67)56-34(65)19-54-37(69)25(6-3-13-52-44(48)49)58-42(74)32-8-5-15-62(32)43(75)29(17-33(46)64)60-41(31)73/h9-12,25-32H,3-8,13-21H2,1-2H3,(H2,46,64)(H2,47,68)(H,54,69)(H,55,63)(H,56,65)(H,57,71)(H,58,74)(H,59,72)(H,60,73)(H,61,70)(H,66,67)(H4,48,49,52)(H4,50,51,53)
|
||||
InChIKey |
RRPUNOOJZOAZNU-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Glycoprotein IIb/IIIa receptor | Target Info | Modulator | [534473] | |
Reactome | Platelet degranulation | ||||
Elastic fibre formation | |||||
PECAM1 interactions | |||||
Molecules associated with elastic fibres | |||||
Integrin cell surface interactions | |||||
Syndecan interactions | |||||
ECM proteoglycans | |||||
Integrin alphaIIb beta3 signaling | |||||
GRB2:SOS provides linkage to MAPK signaling for Integrins | |||||
p130Cas linkage to MAPK signaling for integrins | |||||
VEGFA-VEGFR2 Pathway | |||||
MAP2K and MAPK activation | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.